UA117833C2 - Склад з відстроченим вивільненням, що містить гранули цистеаміну, і способи його одержання та застосування - Google Patents

Склад з відстроченим вивільненням, що містить гранули цистеаміну, і способи його одержання та застосування

Info

Publication number
UA117833C2
UA117833C2 UAA201600331A UAA201600331A UA117833C2 UA 117833 C2 UA117833 C2 UA 117833C2 UA A201600331 A UAA201600331 A UA A201600331A UA A201600331 A UAA201600331 A UA A201600331A UA 117833 C2 UA117833 C2 UA 117833C2
Authority
UA
Ukraine
Prior art keywords
administration
pellets
substitute
methods
composition containing
Prior art date
Application number
UAA201600331A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кетлін Пауел
Рамеш Мутаварапу
Original Assignee
Раптор Фармасьютікалз Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52019418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117833(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Раптор Фармасьютікалз Інк. filed Critical Раптор Фармасьютікалз Інк.
Publication of UA117833C2 publication Critical patent/UA117833C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Cosmetics (AREA)
UAA201600331A 2013-06-17 2014-06-17 Склад з відстроченим вивільненням, що містить гранули цистеаміну, і способи його одержання та застосування UA117833C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361835965P 2013-06-17 2013-06-17
PCT/US2014/042607 WO2014204881A1 (en) 2013-06-17 2014-06-17 Delayed release cysteamine bead formulation

Publications (1)

Publication Number Publication Date
UA117833C2 true UA117833C2 (uk) 2018-10-10

Family

ID=52019418

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201600331A UA117833C2 (uk) 2013-06-17 2014-06-17 Склад з відстроченим вивільненням, що містить гранули цистеаміну, і способи його одержання та застосування

Country Status (25)

Country Link
US (9) US9233077B2 (enExample)
EP (2) EP3939574A1 (enExample)
JP (1) JP6468661B2 (enExample)
KR (2) KR102281747B1 (enExample)
CN (2) CN110664780B (enExample)
AP (1) AP2015008925A0 (enExample)
AR (2) AR096628A1 (enExample)
AU (1) AU2014281702C1 (enExample)
BR (1) BR112015031417B1 (enExample)
CA (2) CA2938644C (enExample)
CL (1) CL2015003662A1 (enExample)
CU (1) CU20150178A7 (enExample)
EA (1) EA031255B8 (enExample)
HK (1) HK1218066A1 (enExample)
IL (2) IL302141A (enExample)
MX (1) MX375377B (enExample)
NI (1) NI201500177A (enExample)
NZ (1) NZ714517A (enExample)
PH (2) PH12020552266A1 (enExample)
SG (1) SG11201510126QA (enExample)
TN (1) TN2015000549A1 (enExample)
TW (1) TWI649100B (enExample)
UA (1) UA117833C2 (enExample)
WO (1) WO2014204881A1 (enExample)
ZA (1) ZA201508783B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物,以及其製備及使用方法
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
WO2017087532A1 (en) * 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
WO2018093364A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10251850B2 (en) 2017-01-11 2019-04-09 Lupin Limited Process for preparation of cysteamine bitartrate
EA201992178A1 (ru) * 2017-03-15 2020-05-22 Сересин Инк. Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними
EP4545069A4 (en) * 2022-06-24 2026-06-10 Sunsho Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION AND ITS PRODUCTION PROCESS

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4959306A (en) 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20050004075A1 (en) 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
US20030157191A1 (en) 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DK1471902T3 (da) 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005049002A1 (en) 2003-11-19 2005-06-02 Omega Bio-Pharma International Ltd. Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
TWI350751B (en) 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
AU2005240122B2 (en) 2004-05-03 2011-02-17 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
WO2006102965A1 (en) * 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
PT1879599E (pt) 2005-04-20 2014-01-23 Hutchinson Fred Cancer Res Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
WO2007089670A2 (en) * 2006-01-27 2007-08-09 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
WO2009070781A1 (en) * 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
US20090209650A1 (en) 2008-02-17 2009-08-20 Francis Chi Materials and Methods for Improving the health of Shrimp
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
JP5619130B2 (ja) * 2009-03-18 2014-11-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングEvonik RoehmGmbH 中性ビニルポリマーおよび賦形剤を含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
CN101653426A (zh) 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
CN101703472B (zh) * 2009-11-09 2011-06-22 上海邦成生物科技有限公司 一种半胱胺盐酸盐制粒包衣缓释产品及其制备方法
CN102077905B (zh) 2010-12-10 2013-01-02 无锡正大畜禽有限公司 一种肠溶盐酸半胱胺包膜颗粒的生产方法
CA2835293C (en) * 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
SG10201800159QA (en) * 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物,以及其製備及使用方法

Also Published As

Publication number Publication date
PH12020552266A1 (en) 2022-04-25
IL302141A (en) 2023-06-01
BR112015031417A8 (pt) 2021-06-22
ZA201508783B (en) 2019-09-25
KR20210094140A (ko) 2021-07-28
US20170319513A1 (en) 2017-11-09
NI201500177A (es) 2016-02-15
CU20150178A7 (es) 2016-07-29
PH12015502783A1 (en) 2016-03-21
US20160095827A1 (en) 2016-04-07
US9233077B2 (en) 2016-01-12
SG11201510126QA (en) 2016-01-28
WO2014204881A8 (en) 2016-02-18
CN105492000B (zh) 2019-11-15
CA2914770C (en) 2016-09-27
JP6468661B2 (ja) 2019-02-13
AR096628A1 (es) 2016-01-20
EP3010491A4 (en) 2016-05-18
AR128816A2 (es) 2024-06-19
US20170319514A1 (en) 2017-11-09
KR102281747B1 (ko) 2021-07-26
TWI649100B (zh) 2019-02-01
AU2014281702B2 (en) 2019-11-07
EP3010491A1 (en) 2016-04-27
HK1218066A1 (zh) 2017-02-03
BR112015031417B1 (pt) 2022-12-27
KR20160045053A (ko) 2016-04-26
JP2016523250A (ja) 2016-08-08
US11090279B2 (en) 2021-08-17
EP3939574A1 (en) 2022-01-19
NZ714517A (en) 2018-10-26
BR112015031417A2 (pt) 2017-07-25
CA2914770A1 (en) 2014-12-24
MX2015017366A (es) 2016-07-13
CN110664780B (zh) 2022-09-27
CN105492000A (zh) 2016-04-13
CA2938644C (en) 2019-08-27
WO2014204881A1 (en) 2014-12-24
EA201690036A1 (ru) 2016-09-30
MX375377B (es) 2025-03-06
CA2938644A1 (en) 2014-12-24
US20160331704A1 (en) 2016-11-17
CL2015003662A1 (es) 2016-08-05
EA031255B1 (ru) 2018-12-28
US20170319512A1 (en) 2017-11-09
US20190298665A1 (en) 2019-10-03
TW201534357A (zh) 2015-09-16
AU2014281702C1 (en) 2020-05-14
KR102466253B1 (ko) 2022-11-10
AU2014281702A1 (en) 2015-12-10
US20160158170A1 (en) 2016-06-09
TN2015000549A1 (en) 2017-04-06
US9173851B1 (en) 2015-11-03
EA031255B8 (ru) 2019-11-29
US20140370085A1 (en) 2014-12-18
AP2015008925A0 (en) 2015-12-31
CN110664780A (zh) 2020-01-10
US20150290139A1 (en) 2015-10-15
IL284823A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
MX378273B (es) Compuestos activos hacia bromodominios.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201792613A1 (ru) Модуляторы cot и способы их применения
CL2016002455A1 (es) Anticuerpos multiespecíficos.
PL4000608T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX375377B (es) Formulación de perlas de cisteamina de liberación retardada.
HUE043697T2 (hu) Készítmények és eljárások HBV és TTR expressziójának modulálására
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
MX2015013247A (es) Formulacion de acetato de abiraterona.
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
GEAP201813996A (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
MX2015016603A (es) Composiciones de corticosteroides.
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
HUE045492T2 (hu) Porlasztható, helyileg alkalmazható hordozóanyag és foszfatidilkolint tartalmazó készítmény
CL2015003672A1 (es) Fabricación de composición explosiva y plataforma de entrega, y métodos explosivos
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
HUE046673T2 (hu) Anti-EpCAM antitestek és alkalmazási eljárások
IL246202A0 (en) Methods for t-cell epitope sorting, preparation of t-cell preparations and treatment of diseases
WO2014107596A8 (en) Compositions and methods for polynucleotide transfection
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
MX2016005545A (es) Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.